Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

65.48USD
21 Feb 2017
Change (% chg)

$0.09 (+0.14%)
Prev Close
$65.39
Open
$65.07
Day's High
$65.78
Day's Low
$65.01
Volume
2,550,035
Avg. Vol
3,333,327
52-wk High
$65.87
52-wk Low
$49.64

Select another date:

Tue, Feb 14 2017

Merck stopping late stage study as another Alzheimer's drug fails

Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.

UPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails

Feb 14 Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.

Merck to halt study of mild to moderate Alzheimer's drug

Feb 14 Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel pointed to a lack of effectiveness.

BRIEF-Merck announces Epoch study of Verubecestat

* Merck announces epoch study of verubecestat for the treatment of people with mild to moderate alzheimer's disease to stop for lack of efficacy

BRIEF-Merck's doravirine meets primary efficacy endpoint in pivotal phase 3 trial

* Merck's doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (nnrti) for the treatment of hiv-1 infection, met primary efficacy endpoint in pivotal phase 3 trial

BRIEF-Capital World Investors reports 5.1 pct passive stake in Merck & Co as on Dec 30 - SEC Filing

* Capital World Investors reports 5.1 percent passive stake in Merck & Co Inc as on December 30, 2016 - SEC Filing Source text: [http://bit.ly/2kkIx8A] Further company coverage:

BRIEF-Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies

* Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored Phase 2 clinical trial in ovarian cancer in combination with approved anti-PD-1 drug

BRIEF-Merck says FDA accepts two SBLAs for Keytruda

* FDA accepts two SBLAs for Merck's Keytruda (pembrolizumab) for locally advanced or metastatic urothelial cancer in cisplatin-ineligible first-line and second-line post-platinum failure treatment settings

Merck 2017 forecast reassuring; full-speed ahead with Keytruda

Merck & Co Inc , faced with patent expirations and increasing development costs for its high-profile Keytruda cancer immunotherapy, reassured investors on Thursday with a 2017 profit forecast roughly in line with Wall Street expectations. | Video

UPDATE 3-Merck 2017 forecast reassuring; full-speed ahead with Keytruda

Feb 2 Merck & Co Inc, faced with patent expirations and increasing development costs for its high-profile Keytruda cancer immunotherapy, reassured investors on Thursday with a 2017 profit forecast roughly in line with Wall Street expectations.

Select another date:

More From Around the Web